Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Alvotech(ALVO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALVO
11/12/2026: ALVO (1-star) is currently NOT-A-BUY. Pass it for now.
Alvotech is a specialized biopharmaceutical company focused on the development and manufacturing of biosimilar medicines. The company has a notable position in the industry, backed by its vertically integrated platform and successful recent approvals of products like Simlandi and Selarsdi in major markets. Its primary opportunity lies in capturing share as blockbuster biologics face patent expirations. However, the company faces risks related to regulatory hurdles, intense competition from legacy pharmaceutical firms, and the need for significant R&D capital. This stock is best suited for growth-oriented investors with a high risk tolerance, and observers should monitor upcoming regulatory milestones and commercial adoption metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Alvotech is an early-to-mid-stage growth company aiming to disrupt the biologic market through the biosimilar wave. |
| Momentum investor | Mixed fit | The stock's movement is highly correlated with regulatory and clinical news, making it suitable for those tracking positive catalysts. |
| Value investor | Weak fit | The company is currently in a high-expenditure phase, making traditional value metrics like P/E ratio less relevant. |
| Dividend investor | Weak fit | Alvotech does not pay a dividend and is not currently structured for income-focused investors. |
| Low-risk investor | Weak fit | The binary nature of regulatory outcomes and high R&D costs create significant volatility profile. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical results and regulatory news. |
| Valuation risk | Medium / high | As a growth-stage company, valuation is heavily dependent on future earnings potential rather than current profits. |
| Competition risk (Biosimilar incumbents) | High | Established players have substantial resources and can aggressively defend their market positions. |
| Business quality | Medium | The company has strong technical capabilities but is still maturing its commercial operations. |
| Dividend income | Low / none | Investors should expect zero income generation from this asset. |
| Execution risk | Medium / high | Successful commercialization depends on complex supply chain management and partnership execution. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1.0M shares | Beta 0.24 | 52 Weeks Range 2.94 - 6.53 | Updated Date 11/12/2026 |
52 Weeks Range 2.94 - 6.53 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.62 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 21.98% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue from the sale of biosimilars like Simlandi and Selarsdi. | Alvotech makes money when its products are sold to healthcare providers and pharmacy networks. |
| Partnership/Milestone Fees | Payments from commercialization partners for reaching R&D and regulatory milestones. | Revenue is often boosted by upfront and success-based payments from large pharma partners. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 15.24 | Enterprise Value 3.05B | Price to Sales(TTM) 3.55 |
Enterprise Value 3.05B | Price to Sales(TTM) 3.55 | ||
Enterprise Value to Revenue 6.2 | Enterprise Value to EBITDA 20.11 | Shares Outstanding 356.82M | Shares Floating 140.79M |
Shares Outstanding 356.82M | Shares Floating 140.79M | ||
Percent Insiders 59.68 | Percent Institutions 12.85 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.